| ACE2 of the heart: from angiotensin I to angiotensin (1–7) S Keidar, M Kaplan, A Gamliel-Lazarovich Cardiovascular research 73 (3), 463-469, 2007 | 368 | 2007 |
| Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a … U Milman, S Blum, C Shapira, D Aronson, R Miller-Lotan, Y Anbinder, ... Arteriosclerosis, thrombosis, and vascular biology 28 (2), 341-347, 2008 | 364 | 2008 |
| Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the … S Keidar, M Kaplan, E Pavlotzky, R Coleman, T Hayek, S Hamoud, ... Circulation 109 (18), 2213-2220, 2004 | 315 | 2004 |
| Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients S Keidar, A Gamliel-Lazarovich, M Kaplan, E Pavlotzky, S Hamoud, ... Circulation research 97 (9), 946-953, 2005 | 261 | 2005 |
| Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its … O Hussein, S Schlezinger, M Rosenblat, S Keidar, M Aviram Atherosclerosis 128 (1), 11-18, 1997 | 217 | 1997 |
| Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins S Keidar, M Kaplan, A Hoffman, M Aviram Atherosclerosis 115 (2), 201-215, 1995 | 210 | 1995 |
| Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy M Aviram, O Hussein, M Rosenblat, S Schlezinger, T Hayek, S Keidar Journal of cardiovascular pharmacology 31 (1), 39-45, 1998 | 194 | 1998 |
| The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent … T Hayek, J Attias, R Coleman, S Brodsky, J Smith, JL Breslow, S Keidar Cardiovascular research 44 (3), 579-587, 1999 | 192 | 1999 |
| Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes B Fuhrman, L Koren, N Volkova, S Keidar, T Hayek, M Aviram Atherosclerosis 164 (1), 179-185, 2002 | 186 | 2002 |
| Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets H Osamah, R Mira, S Sorina, K Shlomo, A Michael British journal of clinical pharmacology 44 (1), 77-84, 1997 | 182 | 1997 |
| The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice S Keidar, J Attias, J Smith, JL Breslow, T Hayek Biochemical and biophysical research communications 236 (3), 622-625, 1997 | 180 | 1997 |
| Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized ldl: a possible role for interleukin-6 S Keidar, R Heinrich, M Kaplan, T Hayek, M Aviram Arteriosclerosis, thrombosis, and vascular biology 21 (9), 1464-1469, 2001 | 173 | 2001 |
| Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E–deficient mice S Keidar, T Hayek, M Kaplan, E Pavlotzky, S Hamoud, R Coleman, ... Journal of cardiovascular pharmacology 41 (6), 955-963, 2003 | 160 | 2003 |
| Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice T Hayek, J Attias, J Smith, JL Breslow, S Keidar Journal of cardiovascular pharmacology 31 (4), 540-544, 1998 | 148 | 1998 |
| A mouse model for human atherosclerosis: long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice R Coleman, T Hayek, S Keidar, M Aviram Acta histochemica 108 (6), 415-424, 2006 | 147 | 2006 |
| Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for … S Keidar, M Kaplan, C Shapira, JG Brook, M Aviram Atherosclerosis 107 (1), 71-84, 1994 | 129 | 1994 |
| Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events D Baldassarre, M Amato, L Pustina, S Castelnuovo, S Sanvito, L Gerosa, ... Atherosclerosis 191 (2), 403-408, 2007 | 126 | 2007 |
| Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis S Keidar, J Attias, R Heinrich, R Coleman, M Aviram Atherosclerosis 146 (2), 249-257, 1999 | 122 | 1999 |
| Angiotensin, LDL peroxidation and atherosclerosis S Keidar Life sciences 63 (1), 1-11, 1998 | 121 | 1998 |
| Lesioned low-density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated M Aviram, I Maor, S Keidar, T Hayek, J Oiknine, Y Barel, Z Adler, ... Biochemical and biophysical research communications 216 (2), 501-513, 1995 | 121 | 1995 |
